Immediate Impact

4 from Science/Nature 55 standout
Sub-graph 1 of 22

Citing Papers

NF-κB in biology and targeted therapy: new insights and translational implications
2024 Standout
The Rise of Boron-Containing Compounds: Advancements in Synthesis, Medicinal Chemistry, and Emerging Pharmacology
2024 Standout
2 intermediate papers

Works of Paul Cannell being referenced

Phase I Clinical Trial of Marizomib (NPI-0052) in Patients with Advanced Malignancies Including Multiple Myeloma: Study NPI-0052-102 Final Results
2016
Phase 1 Clinical Evaluation of Twice-Weekly Marizomib (NPI-0052), a Novel Proteasome Inhibitor, in Patients with Relapsed/Refractory Multiple Myeloma (MM)
2011

Author Peers

Author Last Decade Papers Cites
Paul Cannell 509 362 222 283 55 1.1k
M. J. Barnett 671 387 169 219 43 1.2k
Keiko Yumura‐Yagi 592 324 199 241 49 1.1k
Maurizio Musso 672 354 195 326 66 1.3k
P Stryckmans 553 248 277 210 55 1.1k
Katsumichi Fujimaki 406 322 168 297 84 1.0k
Esteban Abella 543 500 175 223 56 1.2k
Oumédaly Reman 621 379 319 354 61 1.4k
Po‐Nan Wang 710 289 352 240 82 1.2k
SJ Proctor 473 251 138 227 54 1000
Pasquale Iacopino 752 401 250 203 69 1.3k

All Works

Loading papers...

Rankless by CCL
2026